·SEC EDGARLow
Duncan Charles Cliff purchased $38K of VNDA
Duncan Charles Cliff purchased 10,000 shares of Vanda Pharmaceuticals Inc. (VNDA) at an average of $3.81 ($3.80–$3.82) across 3 trades over 2026-11-03 to 2026-11-05.
StockNASDAQ · US · USDHealthcare · Biotechnology
$VNDA
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals develops and commercializes medicines for patients with a range of medical conditions. Its commercial products are Fanapt for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder; HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis syndrome; PONVORY for relapsing forms of multiple sclerosis; and NEREUS for preventing motion-induced vomiting. The company also conducts research and development on additional medicines and uses pharmacogenetics and pharmacogenomics expertise in drug discovery, clinical trials and product development. Vanda makes money by commercializing its prescription products, including through distribution partners. It is headquartered in Washington, D.C.
AlphAI earnings readQ3 FY2026 · OCT 28Q3 2026 total net product sales increased 24% to $69.8 million, while total operating expenses decreased 18% compared to Q2 2026 and net loss was $22.6 million.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $VNDAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $VNDA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $38K 3 txs
- Sells
- — 0 txs
Duncan Charles Cliff3× · $38K
10b5-1 share of filings0%
Top stories · $VNDAMore →
·investing.com
H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth
H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.
·hcplive.com
The HCPFive: Top News for Healthcare Providers from the Week of 10/25
Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.
VNDA sentiment & insider activity
Recent VNDA coverage spans earnings, financial news and technology.
In the last 30 days, VNDA insiders filed 3 SEC Form 4 transactions — 3 purchases ($38K) and no sales. The most active reporter was Duncan Charles Cliff with 3 filings.
What's driving VNDA
The insider purchase suggests confidence from a board member, potentially supporting the stock price in the short term.
Earnings beat and upgraded rating suggest upside pressure.
Positive Phase 3 readout increases odds of an FDA label expansion, supporting biotech sentiment and potential near-term sNDA momentum.
Strong revenue growth, expense reduction and positive trial data suggest upside momentum.
Positive pivotal trial results suggest potential FDA approval, likely driving the stock higher.
AlphAI scores every news story that mentions VNDA with an AI model for sentiment and relevance, and aggregates insider trades from Vanda Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $VNDA
Score
Duncan Charles Cliff purchased $38K of VNDA
Duncan Charles Cliff purchased 10,000 shares of Vanda Pharmaceuticals Inc. (VNDA) at an average of $3.81 ($3.80–$3.82) across 3 trades over 2026-11-03 to 2026-11-05.
H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth
H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.
The HCPFive: Top News for Healthcare Providers from the Week of 10/25
Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8M, up 24% YoY, and operating expenses of $93.3M, down 18% QoQ. The company announced positive Phase III results for NEREUS™ in GLP-1-induced vomiting and expects to launch BYSANTI™ in Q4 2026. Quimilza™ BLA for GPP is under FDA review with a PDUFA date of December 12, 2026.
Vanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 Study
Vanda Pharmaceuticals (VNDA) reported positive Phase 3 study results for NEREUS, showing a 27% reduction in vomiting episodes compared to placebo. The drug also met key secondary endpoints. Vanda plans to discuss results with the FDA and file a supplemental New Drug Application. VNDA stock was up 1.52% in pre-market trading.
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals (VNDA) will release its Q3 2026 financial results on October 28, 2026, after market close. A conference call will follow, with details provided for participation and replay. Vanda is a biopharmaceutical company focused on innovative therapies.
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Vanda Pharmaceuticals (VNDA) reported that its Phase III study of VQW-765 for social anxiety disorder did not meet the primary endpoint, failing to show a significant difference from placebo. The study evaluated 546 adults and did not confirm earlier Phase II results. The company plans to analyze the full dataset before deciding next steps. VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor partial agonist.
Vanda’s Tasimelteon Study Completion: What Sleep Trial Progress Means for VNDA Investors
Vanda Pharmaceuticals (VNDA) completed a Phase 3 trial of tasimelteon for delayed sleep-wake phase disorder. The study, comparing the drug to a placebo, aims to improve sleep timing and assess safety. Positive results could expand tasimelteon's use and boost VNDA's revenue forecasts, though market reaction depends on detailed outcomes.
Wainwright reiterates Buy on Vanda stock after sleep disorder trial
H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.
Vanda posts late-stage trial win for HETLIOZ in DSWPD (VNDA)
Vanda Pharmaceuticals (VNDA) reported positive late-stage trial results for Hetlioz in treating adults with delayed sleep-wake phase disorder, aiming for FDA label expansion.